{"filings":[{"id":172431,"accession_number":"0001683168-25-000479","cik":1411057,"company_name":"Cannabis Bioscience International Holdings, Inc.","ticker":"CBIH","form_type":"8-K","filed_at":"2025-01-22T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Cannabis Bioscience issues 250M shares to director John Jones for $75,000 with price guarantee","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Director John Jones purchased 250M shares at $0.0003 each for total $75,000 in private placement.","Board authorized transaction as conflicting interest transaction under Colorado law; disinterested directors approved.","Company must repurchase shares for $93,750 if market value below that on Dec 31, 2025, unless stock price exceeds $0.000375.","Shares issued under exemption from registration; outstanding shares pre-issuance were 10,506,749,347."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":2325350.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189428,"accession_number":"0001683168-24-008403","cik":1411057,"company_name":"Cannabis Bioscience International Holdings, Inc.","ticker":"CBIH","form_type":"8-K","filed_at":"2024-11-26T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Appoints Charles Tamburello to board; 100M shares as compensation","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Charles Tamburello appointed director effective Dec 1, 2024; board expands from three to four.","Tamburello, CEO of Global Discovery Group, recruited for M&A expertise; receives no cash, 100M restricted shares.","If removed for cause or resigns before Nov 30, 2025, must return 8.33M shares per full month remaining.","Board also created a single-director Executive Committee on Nov 15, 2024, with limited authority per Colorado law."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2325350.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205935,"accession_number":"0001683168-24-005950","cik":1411057,"company_name":"Cannabis Bioscience International Holdings, Inc.","ticker":"CBIH","form_type":"8-K","filed_at":"2024-08-22T23:59:59+00:00","items":["1.01","5.02","5.03","8.01","9.01"],"status":"ready","headline":"Cannabis Bioscience appoints John Jones director/treasurer; awards 125M shares annually; adopts clawback policy","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John Jones appointed director and treasurer; agrees to make $37,500 payment under Diagonal SPA by Sept 15, 2024.","Jones and Kamienski reduce note interest to 2.5% monthly, monthly payment to $5,000 on $291,451 principal note.","Jones to receive 125M shares of common stock annually on each May 31 from 2025-2028 if serving as treasurer.","Jose Torres receives 125M shares for 2024 secretary services, with similar amounts in 2025-2027.","Vita Biotech to pay Alpha $50,000/month for 4-month term for clinical trials; Series B Preferred shares increased to 2,000."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2325350.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242437,"accession_number":"0001683168-24-001817","cik":1411057,"company_name":"Cannabis Bioscience International Holdings, Inc.","ticker":"CBIH","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Cannabis Bioscience International enters $66K convertible note with 1800 Diagonal Lending LLC","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Principal $66,000; net proceeds $50,000 after OID ($11,000), interest charge ($8,580), and $5,000 fees.","Repayment in 5 installments: $37,290 on Sep 15, 2024, then $9,322.50 monthly through Jan 15, 2025.","Upon default, note convertible at 65% of lowest trading price over prior 10 trading days.","Company must reserve 3x shares issuable upon conversion; initial reserve 435,164,835 shares.","Breach of representations or covenants triggers event of default; 150% liquidated damages."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":2325350.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259824,"accession_number":"0001683168-23-008853","cik":1411057,"company_name":"Cannabis Bioscience International Holdings, Inc.","ticker":"CBIH","form_type":"8-K","filed_at":"2023-12-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cannabis Bioscience board approves 6.25B share offering at $0.0008/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved Subscription Agreement for up to 6,250,000,000 shares of common stock at $0.0008 per share.","Offering made under S-1 registration statement (File 333-267039) declared effective December 5, 2023.","Existing shareholders may also offer and sell up to 3,837,154,885 shares under the same prospectus."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2325350.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}